A widely recommended approach for the control of hyperglycemia is to administer a parenteral insulin preparation that provides a constant addition of circulating insulin for 12–24 h to augment or replace the deficient endogenous insulin secretion [3, 4], although insulin resistance is initially recognized in insulin-treated patients. Here, INS is linked to Hyperglycemia.